SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2004
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon |
|
0-22613 |
|
93-0797222 |
(State
or other jurisdiction of |
|
(Commission File Number) |
|
(IRS
Employer |
One S.W. Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrants telephone number, including area code
Item 5. Other Events and Regulation FD Disclosure.
The information set forth below pursuant to Item 12 shall also be deemed filed pursuant to Item 5.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated January 8, 2004 announced retention of a consultant with significant industry experience to provide strategic direction and management of the companys ongoing regulatory and clinical development programs. |
Item 12. Results of Operations and Financial Condition.
Company issued a press release on January 8, 2004, before the opening of trading in its Common Stock on the Nasdaq National Market System. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
The Press Release dated January 8, 2004 announced retention of a consultant with significant industry experience to provide strategic direction and management of the companys ongoing regulatory and clinical development programs.
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on January 9, 2004.
|
AVI BioPharma, Inc. |
||
|
|
|
|
|
By: |
/s/ ALAN P.TIMMINS |
|
|
|
Alan P. Timmins |
3
Exhibit 99.1
Text of Press Release
Company Contacts:
AVI BioPharma, Inc.
Michael Hubbard (hubbard@avibio.com)
(503) 227-0554
Lippert/Heilshorn & Associates Inc.
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
(310) 691-7100
Press Contacts:
Waggener Edstrom Bioscience
Wendy Carhart (wendyc@wagged.com)
(503) 443-7000
For Release 6 a.m. PST
Jan. 8, 2004
AVI BioPharma Bolsters Clinical and Regulatory Expertise
PORTLAND, Ore. Jan. 8, 2004 AVI BioPharma, Inc. (Nasdaq: AVII), has entered into a consulting agreement with James T. Gourzis, M.D., Ph.D., to provide strategic direction and management of the companys ongoing regulatory and clinical development programs. Gourzis brings more than 30 years of experience to AVI in designing and leading clinical trials, implementing regulatory strategies, and negotiating licensing transactions.
We are pleased to have Dr. Gourzis join our team, as his extensive product development and regulatory experience are well-suited to AVIs strategic goals for 2004 and beyond, said Denis R. Burger, Ph.D., chief executive officer of AVI BioPharma. As we continue to advance our clinical development programs, James licensing experience and FDA knowledge will bring additional strength to the execution of our corporate strategies.
David H. Mason Jr., M.D., senior vice president for clinical development and regulatory affairs, resigned from the company to move east to pursue opportunities closer to his family. David successfully undertook numerous projects during his three years at AVI, including support for the construction and startup of our GMP manufacturing facility, Burger said. We appreciate his contributions to AVI and wish him every success in his new endeavors.
Most recently, Gourzis provided consulting services to a wide range of biotechnology and medical device companies with respect to scientific, strategic and regulatory considerations associated with drug and biologic development. Before his role as a consultant, Gourzis was an executive with PAREXEL International Corp., a contract research organization that provides a range of services to pharmaceutical and biotechnology companies throughout the entire product life cycle. Gourzis began his career in the clinical research groups of McNeil Laboratories Inc. and Schering Corp. Gourzis has experience in a broad range of therapeutic areas, including cardiology, immunology and infectious disease.
Gourzis received a bachelors degree in biology from Harvard University, a masters degree in pharmacology from Boston University, and his M.D. from the University of Manitoba, Winnipeg, Canada. Gourzis also received a doctorate in pharmacology from the University of Manitoba.
In addition to tapping Gourzis expertise, AVI is conducting an extensive search for an executive to lead its clinical and regulatory efforts on a permanent basis.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NeuGene® antisense drugs and cancer immunotherapy. AVIs lead NeuGene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVIs antiviral program uses NeuGene antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVIs second technology, AVICINE®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic cancer. More information about AVI is available on the companys Web site at http://www.avibio.com/.
# # #
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the companys Securities and Exchange Commission filings.